Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 11976320 
Chen BC, Wu WT, Ho FM, Lin WW (2002) Inhibition of interleukin-1beta -induced NF-kappa B activation by calcium/calmodulin-dependent protein kinase kinase occurs through Akt activation associated with interleukin-1 receptor-associated kinase phosphorylation and uncoupling of MyD88. J Biol Chem 277, 24169-79 11976320
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

T308-p - Akt1 (human)
Orthologous residues
Akt1 (human): T308‑p, Akt1 (mouse): T308‑p, Akt1 (rat): T308‑p, Akt1 (fruit fly): T423‑p, Akt1 (cow): T308‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-1b increase
ionomycin increase
CAMKK1 (human) increase
ionomycin CAMKK1 (human) no effect upon treatment-induced increase
Akt1 (human) increase wild-type Akt overexpression
ionomycin Akt1 (human) augment treatment-induced increase
CAMKK1 (human) Akt1 (human) augment treatment-induced increase
ionomycin CAMKK1 (human) Akt1 (human) augment treatment-induced increase

S473-p - Akt1 (human)
Orthologous residues
Akt1 (human): S473‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-1b increase
ionomycin no change compared to control
CAMKK1 (human) no change compared to control
ionomycin CAMKK1 (human) no change compared to control
Akt1 (human) increase wild-type Akt1 overexpression
ionomycin Akt1 (human) no effect upon treatment-induced increase
CAMKK1 (human) Akt1 (human) no effect upon treatment-induced increase
ionomycin CAMKK1 (human) Akt1 (human) no effect upon treatment-induced increase

T100-p - IRAK1 (human)
Orthologous residues
IRAK1 (human): T100‑p, IRAK1 iso4 (human): T100‑p, IRAK1 (mouse): T100‑p, IRAK1 (rat): T100‑p
Characterization
 Methods used to characterize site in vivo immunoprecipitation, mutation of modification site, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE Akt1 (human)
Downstream Regulation
 Effect of modification (process):  transcription, inhibited


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.